Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Thorough in silico and in vitro cDNA analysis of 21 putative BRCA1 and BRCA2 splice variants and a complex tandem duplication in BRCA2 allowing the identification of activated cryptic splice donor sites in BRCA2 exon 11

A. Baert, E. Machackova, I. Coene, C. Cremin, K. Turner, C. Portigal-Todd, MJ. Asrat, J. Nuk, A. Mindlin, S. Young, A. MacMillan, T. Van Maerken, M. Trbusek, W. McKinnon, ME. Wood, WD. Foulkes, M. Santamariña, M. de la Hoya, L. Foretova, B....

. 2018 ; 39 (4) : 515-526. [pub] 20180122

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028648

Grantová podpora
FDN-148390 CIHR - Canada

For 21 putative BRCA1 and BRCA2 splice site variants, the concordance between mRNA analysis and predictions by in silico programs was evaluated. Aberrant splicing was confirmed for 12 alterations. In silico prediction tools were helpful to determine for which variants cDNA analysis is warranted, however, predictions for variants in the Cartegni consensus region but outside the canonical sites, were less reliable. Learning algorithms like Adaboost and Random Forest outperformed the classical tools. Further validations are warranted prior to implementation of these novel tools in clinical settings. Additionally, we report here for the first time activated cryptic donor sites in the large exon 11 of BRCA2 by evaluating the effect at the cDNA level of a novel tandem duplication (5' breakpoint in intron 4; 3' breakpoint in exon 11) and of a variant disrupting the splice donor site of exon 11 (c.6841+1G > C). Additional sites were predicted, but not activated. These sites warrant further research to increase our knowledge on cis and trans acting factors involved in the conservation of correct transcription of this large exon. This may contribute to adequate design of ASOs (antisense oligonucleotides), an emerging therapy to render cancer cells sensitive to PARP inhibitor and platinum therapies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028648
003      
CZ-PrNML
005      
20190822124306.0
007      
ta
008      
190813s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/humu.23390 $2 doi
035    __
$a (PubMed)29280214
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Baert, Annelot $u Department of Basic Medical Sciences, Ghent University, Ghent, Belgium. Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
245    10
$a Thorough in silico and in vitro cDNA analysis of 21 putative BRCA1 and BRCA2 splice variants and a complex tandem duplication in BRCA2 allowing the identification of activated cryptic splice donor sites in BRCA2 exon 11 / $c A. Baert, E. Machackova, I. Coene, C. Cremin, K. Turner, C. Portigal-Todd, MJ. Asrat, J. Nuk, A. Mindlin, S. Young, A. MacMillan, T. Van Maerken, M. Trbusek, W. McKinnon, ME. Wood, WD. Foulkes, M. Santamariña, M. de la Hoya, L. Foretova, B. Poppe, A. Vral, T. Rosseel, K. De Leeneer, A. Vega, KBM. Claes,
520    9_
$a For 21 putative BRCA1 and BRCA2 splice site variants, the concordance between mRNA analysis and predictions by in silico programs was evaluated. Aberrant splicing was confirmed for 12 alterations. In silico prediction tools were helpful to determine for which variants cDNA analysis is warranted, however, predictions for variants in the Cartegni consensus region but outside the canonical sites, were less reliable. Learning algorithms like Adaboost and Random Forest outperformed the classical tools. Further validations are warranted prior to implementation of these novel tools in clinical settings. Additionally, we report here for the first time activated cryptic donor sites in the large exon 11 of BRCA2 by evaluating the effect at the cDNA level of a novel tandem duplication (5' breakpoint in intron 4; 3' breakpoint in exon 11) and of a variant disrupting the splice donor site of exon 11 (c.6841+1G > C). Additional sites were predicted, but not activated. These sites warrant further research to increase our knowledge on cis and trans acting factors involved in the conservation of correct transcription of this large exon. This may contribute to adequate design of ASOs (antisense oligonucleotides), an emerging therapy to render cancer cells sensitive to PARP inhibitor and platinum therapies.
650    12
$a alternativní sestřih $7 D017398
650    _2
$a nádory prsu $x genetika $7 D001943
650    _2
$a počítačová simulace $7 D003198
650    _2
$a komplementární DNA $7 D018076
650    _2
$a exony $x genetika $7 D005091
650    _2
$a ženské pohlaví $7 D005260
650    12
$a geny BRCA1 $7 D019398
650    12
$a geny BRCA2 $7 D024522
650    _2
$a genetická variace $7 D014644
650    _2
$a lidé $7 D006801
650    _2
$a mutace $7 D009154
650    _2
$a nádory vaječníků $x genetika $7 D010051
650    12
$a místa sestřihu RNA $7 D022821
650    _2
$a messenger RNA $x genetika $7 D012333
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Machackova, Eva $u Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Coene, Ilse $u Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
700    1_
$a Cremin, Carol $u BC Cancer Agency, Vancouver, British Columbia, Canada.
700    1_
$a Turner, Kristin $u BC Cancer Agency, Vancouver, British Columbia, Canada.
700    1_
$a Portigal-Todd, Cheryl $u BC Cancer Agency, Vancouver, British Columbia, Canada.
700    1_
$a Asrat, Marie Jill $u BC Cancer Agency, Vancouver, British Columbia, Canada.
700    1_
$a Nuk, Jennifer $u BC Cancer Agency, Vancouver, British Columbia, Canada.
700    1_
$a Mindlin, Allison $u BC Cancer Agency, Vancouver, British Columbia, Canada.
700    1_
$a Young, Sean $u BC Cancer Agency, Vancouver, British Columbia, Canada. Cancer Genetics and Genomics Laboratory, Department of Pathology and Laboratory Medicine, BC Cancer Agency, Vancouver, British Columbia, Canada.
700    1_
$a MacMillan, Andree $u Provincial Medical Genetics Program, Eastern Health, St. John's, Newfoundland and Labrador, Canada.
700    1_
$a Van Maerken, Tom $u Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
700    1_
$a Trbusek, Martin $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
700    1_
$a McKinnon, Wendy $u Familial Cancer Program, University of Vermont Medical Center, Burlington, Vermont, United States.
700    1_
$a Wood, Marie E $u Familial Cancer Program, University of Vermont Medical Center, Burlington, Vermont, United States.
700    1_
$a Foulkes, William D $u Cancer Research Program, Research Institute of the McGill University Health Centre, McGill University, Montreal, Quebec, Canada.
700    1_
$a Santamariña, Marta $u Fundación Pública Galega de Medicina Xenómica-SERGAS, Grupo de Medicina Xenómica, CIBERER, IDIS, Santiago de Compostela, Spain.
700    1_
$a de la Hoya, Miguel $u Molecular Oncology Laboratory CIBERONC, Hospital Clinico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Madrid, Spain.
700    1_
$a Foretova, Lenka $u Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Poppe, Bruce $u Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
700    1_
$a Vral, Anne $u Department of Basic Medical Sciences, Ghent University, Ghent, Belgium.
700    1_
$a Rosseel, Toon $u Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
700    1_
$a De Leeneer, Kim $u Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
700    1_
$a Vega, Ana $u Fundación Pública Galega de Medicina Xenómica-SERGAS, Grupo de Medicina Xenómica, CIBERER, IDIS, Santiago de Compostela, Spain.
700    1_
$a Claes, Kathleen B M $u Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
773    0_
$w MED00002078 $t Human mutation $x 1098-1004 $g Roč. 39, č. 4 (2018), s. 515-526
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29280214 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190822124545 $b ABA008
999    __
$a ok $b bmc $g 1433797 $s 1067108
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 39 $c 4 $d 515-526 $e 20180122 $i 1098-1004 $m Human mutation $n Hum Mutat $x MED00002078
GRA    __
$a FDN-148390 $p CIHR $2 Canada
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Možnosti archivace